Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Published:2021-04-08 Issue:14 Volume:384 Page:1289-1300
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Motzer Robert¹,Alekseev Boris¹,Rha Sun-Young¹,Porta Camillo¹,Eto Masatoshi¹,Powles Thomas¹,Grünwald Viktor¹,Hutson Thomas E.¹,Kopyltsov Evgeny¹,Méndez-Vidal María J.¹,Kozlov Vadim¹,Alyasova Anna¹,Hong Sung-Hoo¹,Kapoor Anil¹,Alonso Gordoa Teresa¹,Merchan Jaime R.¹,Winquist Eric¹,Maroto Pablo¹,Goh Jeffrey C.¹,Kim Miso¹,Gurney Howard¹,Patel Vijay¹,Peer Avivit¹,Procopio Giuseppe¹,Takagi Toshio¹,Melichar Bohuslav¹,Rolland Frederic¹,De Giorgi Ugo¹^ORCID,Wong Shirley¹,Bedke Jens¹,Schmidinger Manuela¹,Dutcus Corina E.¹,Smith Alan D.¹,Dutta Lea¹,Mody Kalgi¹,Perini Rodolfo F.¹,Xing Dongyuan¹,Choueiri Toni K.¹

Affiliation:

1. From Memorial Sloan Kettering Cancer Center, New York (R.M.); P. Hertsen Moscow Oncology Research Institute, Moscow (B.A.), the State Institution of Health Care Regional Clinical Oncology Dispensary, Omsk (E.K.), the State Budgetary Health Care Institution Novosibirsk Regional Clinical Oncology Dispensary, Novosibirsk (V.K.), and Prevoljskiy Region Medical Center, Novgorod (A.A.) — all in Russia; Yonsei Cancer Center, Yonsei University Health System (S.Y.R.), Seoul St. Mary’s Hospital, Catholic...

Funder

Eisai Inc.

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716

Cited by 934 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What factors may affect the effect of ICI-combined therapy in patients with metastatic renal cell carcinoma? A meta-analysis;Immunopharmacology and Immunotoxicology;2024-02-06

2. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy;Targeted Oncology;2024-02-03

3. Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis;Frontiers in Cardiovascular Medicine;2024-02-02

4. Das fortgeschrittene Nierenzellkarzinom – Aktuelle Systemtherapie im Überblick;TumorDiagnostik & Therapie;2024-02

5. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors;JTO Clinical and Research Reports;2024-02